JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Sarkaria J, Mrugala M, Jaeckle K, Burns T, Vaubel R, Parney I, Chaichana K, Clement P, Martínez-García M, Sanchez J, Omuro A, Pronk L, Ross H, Teufel M, Hesse R, Grempler R, Galanis E. JS07.4.A A PHASE 0/IA STUDY OF BRIGIMADLIN CONCENTRATION IN BRAIN TISSUE AND A DOSE ESCALATION STUDY OF BRIGIMADLIN PLUS RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology 2024, 26: v13-v13. PMCID: PMC11485993, DOI: 10.1093/neuonc/noae144.036.Peer-Reviewed Original ResearchNon-contrast-enhancedMouse double minute 2Contrast enhancementMGMT promoter unmethylated glioblastomaPatient-derived xenograft modelsUnbound concentrationsCalculated unbound concentrationsNewly diagnosed GBMMaximum tolerated doseNewly diagnosed glioblastomaTumor cell apoptosisSingle-arm trialMDM2-p53 antagonistsDouble minute 2Restore wild-typeBrain tissueBrain tumor tissueTP53 WTUnmethylated glioblastomaPhase 0Diagnosed glioblastomaTolerated doseOpen-labelP53 target gene expressionIDH-wt